Related Experiment Videos
Lipid-based antifungal agents: current status
1Mycology Unit, Department of Microbiology and Clinical Microbiology, Hacettepe University Medical School, Ankara, 06100, Turkey.
Abstract:
Immunocompromised patients are well known to be predisposed to developing invasive fungal infections. These infections are usually difficult to diagnose and more importantly, the resulting mortality rate is high. The limited number of antifungal agents available and their high rate of toxicity are the major factors complicating the issue. However, the development of lipid-based formulations of existing antifungal agents has opened a new era in antifungal therapy. The best examples are the lipid-based amphotericin B preparations, amphotericin B lipid complex (ABLC; Abelcet), amphotericin B colloidal dispersion (ABCD; Amphotec or Amphocil), and liposomal amphotericin B (AmBisome). These formulations have shown that antifungal activity is maintained while toxicity is reduced. This progress is followed by the incorporation of nystatin into liposomes. Liposomal nystatin formulation is under development and studies of it have provided encouraging data. Finally, lipid-based formulations of hamycin, miconazole, and ketoconazole have been developed but remain experimental. Advances in technology of liposomes and other lipid formulations have provided promising new tools for management of fungal infections.
Insights
Lipid-based antifungal formulations improve treatment for immunocompromised patients. These advanced therapies maintain antifungal activity while significantly reducing toxicity, offering new hope for managing invasive fungal infections.
Area of Science:
- Pharmacology
- Mycology
- Drug Delivery Systems
Background:
- Invasive fungal infections pose a significant threat to immunocompromised patients, characterized by diagnostic challenges and high mortality rates.
- Limited antifungal agents and their inherent toxicity complicate treatment strategies for these vulnerable populations.
Purpose of the Study:
- To review the advancements in lipid-based formulations of antifungal agents.
- To highlight the therapeutic benefits of these novel drug delivery systems in managing invasive fungal infections.
Main Methods:
- Review of existing literature on lipid-based antifungal formulations.
- Analysis of clinical data for lipid-based amphotericin B preparations (ABLC, ABCD, AmBisome).
- Examination of emerging liposomal formulations including nystatin, hamycin, miconazole, and ketoconazole.
Main Results:
- Lipid-based amphotericin B formulations demonstrate maintained antifungal efficacy with reduced toxicity compared to conventional forms.
- Liposomal nystatin is under development with promising preliminary data.
- Experimental lipid-based formulations of hamycin, miconazole, and ketoconazole show potential.
Conclusions:
- Lipid formulations represent a significant advancement in antifungal therapy, improving patient outcomes.
- Technological progress in liposomes and lipid formulations offers promising new strategies for invasive fungal infection management.